Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $900000.0.

  • Foghorn Therapeutics' Depreciation & Amortization (CF) rose 2857.14% to $900000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 346.21%. This contributed to the annual value of $3.1 million for FY2024, which is 1085.71% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Depreciation & Amortization (CF) of $900000.0 as of Q3 2025, which was up 2857.14% from $900000.0 recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Depreciation & Amortization (CF) peaked at $900000.0 during Q3 2022, and registered a low of $700000.0 during Q3 2024.
  • For the 5-year period, Foghorn Therapeutics' Depreciation & Amortization (CF) averaged around $827578.9, with its median value being $811000.0 (2022).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 30000.0% in 2021, then plummeted by 2222.22% in 2024.
  • Foghorn Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $810000.0 in 2021, then grew by 1.36% to $821000.0 in 2022, then grew by 9.62% to $900000.0 in 2023, then dropped by 20.0% to $720000.0 in 2024, then increased by 25.0% to $900000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $900000.0 in Q3 2025, compared to $900000.0 in Q2 2025 and $827000.0 in Q1 2025.